Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine the Phase II doses and to evaluate the safety of
administering bexarotene (Targretin®) daily in combination with oral erlotinib (Tarceva™) to
patients with advanced aerodigestive tract cancers.
Secondary objectives: To evaluate the response rates, progression-free survival and overall
survival of patients with advanced aerodigestive tract cancers treated with bexarotene
(Targretin®) in combination with erlotinib (Tarceva™). To investigate the activity of this
targeted combination therapy by evaluating changes in molecular markers from pre- and
post-treatment buccal swab samples.